Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Travel Through France's Most Iconic Wine Regions By Train On An Immersive Seven-Day Journey - 2Doctor's orders: Eat ice cream, and other tips for a long and healthy life
- 3The Main 15 Applications for Efficiency and Association
- 4EPA watchdog finds nation’s most contaminated sites are vulnerable to flooding, wildfires
- 5More than 800 flights canceled as FAA cuts traffic at 40 major airports. Here's what to know.
- Kids get diseases like lupus, too. As researchers hunt better treatments, this camp brings joy
- Carry Nature Inside with These Staggering Plant Decisions
- 'Dancing with the Stars' semifinals: How to watch Episode 10 tonight, where to stream, who's left and more
- The 3 little words TV fans can't stop obsessing over
- Photos: Presidential turkey pardons — a look back
- A Manual for Nations with Extraordinary Food
- Study casts doubt on potential for life on Jupiter's moon Europa
- Step by step instructions to Open a Lovely Waterway Voyage Insight: Conveniences, Administrations, and Elite Offers
- Spots to Go Hang Floating
